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Abstract: Human Glyco_18 domain-containing proteins constitute a family of chitinases and chitinase-like proteins. Chi-
totriosidase and AMCase are true enzymes which hydrolyse chitin and have a C-terminal chitin-binding domain. YKL-40, 
YKL-39, SI-CLP and murine YM1/2 proteins possess solely Glyco_18 domain and do not have the hydrolytic activity. The 
major sources of Glyco_18 containing proteins are macrophages, neutrophils, epithelial cells, chondrocytes, synovial cells, 
and cancer cells. Both macrophages and neutrophils use the regulated secretory mechanism for the release of Glyco_18 
containing proteins. Glyco_18 containing proteins are established biomarkers for human diseases. Chitotriosidase is over-
produced by lipid-laden macrophages and is a major marker for the inherited lysosomal storage Gaucher disease. AMCase 
and murine lectin YM1 are upregulated in Th2-environment, and enzymatic activity of AMCase contributes to asthma 
pathogenesis. YKL proteins act as soluble mediators for the cell proliferation and migration, and are also involved in rheu-
matoid arthritis, inﬂ  ammatory bowel disease, hepatic ﬁ  brosis and cirrhosis. Chitotriosidase and YKL-40 reﬂ  ect the macro-
phage activation in atherosclerotic plaques. Serum level of YKL-40 is a diagnostic and prognostic marker for numerous 
types of solid tumors. YKL-39 is a marker for the activation of chondrocytes and the progression of the osteoarthritis in 
human. Recently identiﬁ  ed SI-CLP is upregulated by Th2 cytokine IL-4 as well as by glucocorticoids. This unique feature 
of SI-CLP makes it an attractive candidate for the examination of individual sensitivity of patients to glucocorticoid treat-
ment and prediction of side effects of glucocorticoid therapy. Human chitinases and chitinase-like proteins are found in 
tissues and circulation, and can be detected by non-invasive technologies.
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Family Composition: Domain Organisation, Enzymatic Activity 
and Lectin Properties
The common feature of mammalian chitinases and chitinase-like proteins is the presence of highly 
conserved Glyco_18 domain. The Glyco_18 domain is characteristic for the evolutionary conservative 
chitinases, which belong to the glycosyl hydrolase family 18. Family 18 chitinases are distributed in a 
wide range of organisms, including bacteria, plants, fungi, insects, viruses, protozoan parasites, and more 
recently were identiﬁ  ed in mammals. Family 18 chitinases catalyze the hydrolysis of chitin via substrate-
assisted mechanism. An additional activity of these enzymes is trans-glycosylation resulting in the 
formation of chitin oligomers longer than the initial substrate (Sasaki et al. 2002). After cellulose, chitin 
is the second most abundant polysaccharide in nature. Chitin is a polymer of N-acetylglucosamine that 
is a component of fungal cell walls, exoskeletons of insects and crustaceans, and microﬁ  larial sheaths 
of parasitic nematodes. Chitinase production plays a role in the life cycle of chitin-containing fungi and 
parasites; but there is no endogenous chitin in mammals. Evolutionary conserved function of chitinases 
in lower life forms is a host-defence against chitin-containing organisms (Elias et al. 2005). 
There are six Glyco_18 domain-containing proteins identiﬁ  ed in human up to date (see Fig. 1A). In 
addition two closely related Glyco_18 domain-containing proteins, YM1 and YM2, have been reported 
in rodents. However, there are no human analogues for YM1/YM2 neither on genomic nor on protein 
level. Only two mammalian Glyco_18 containing proteins possess enzymatic activity: chitotriosidase 
(Renkema et al. 1995; Boot et al. 1995) and acidic mammalian chitinase AMCase (Boot et al. 2001). 
Chitotriosidase is able to hydrolyse the artiﬁ  cial substrate 4-MU-chitotrioside as well as chitin (Renkema 
et al. 1995). In the excess of substrate, chitotriosidase exhibit trans-glycosylation activity toward substrate 
molecules (Aguilera et al. 2003). AMCase is also capable of cleaving both natural chitin from fungal cell Biomarker Insights 2007: 2 129
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wall and crab shell, and artificial chitin-like 
substrates. In contrast to chitotriosidase, AMCase 
is extremely acid-stable and shows second pH 
optimum around pH 2 (Boot et al. 2001). The cata-
lytic activity of Glyco_18 domain-proteins is 
deﬁ  ned by the presence of a catalytic glutamic acid 
in the context of a DXDXE site located directly 
(with one aminoacid as a spacer) after the charac-
teristic aminoacid triplet FDG (Fusetti et al. 2002). 
Both chitotriosidase and AMCase in addition to 
Glyco_18 domain, contain the functional chitin-
binding domain on their C-terminus. 
YKL-39, YKL-40, SI-CLP and YM1/YM2 are 
composed solely out of Glyco_18 domain. 
Oviductin/MUC9 contains a Glyco_18 domain and 
a long fragment with numerous sites for O-
glycosylation, characteristic of mucins. YKL-39, 
YKL-40, SI-CLP, YM1/YM2 and oviductin lack 
critical aminoacids within the catalytic site 
(Fig. 1B) and do not exhibit enzymatic activity. 
The exchange of glutamic residues in catalytic 
centre of chitotriosidase to leucine, which is 
present in YKL-40 in the same position, converts 
the catalytically active site into chitin-binding site 
(Renkema et al. 1998). Accordingly, YKL-40 was 
established to be a chitin-speciﬁ  c lectin (Renkema 
et al. 1998). Binding of chitin fragments of different 
lengths identiﬁ  ed nine sugar binding subsites in 
the groove in YKL-40, and showed that the speci-
ﬁ  city of its chitin-binding depends on the length 
Figure 1. SI-CLP is a novel member of Glyco_18 domain-containing human chitinases and chitinase-like proteins. (A) Schematic represen-
tation of domain organisation of mammalian Glyco_18 domain-containing protein. (B) Critical aminoacid in catalytic sites. The characteristic 
FDG sequence preceding catalytic motif is shown in shadowed box. Catalytic aminoacids are shown in bold. Complete active catalytic 
motifs are underlined (Kzhyshkowska et al. 2006). This research was originally published in Blood. Kzhyshkowska, J et al. Novel stabilin-1 
interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway Blood. 
2006; 107:3221-3228. © the American Society of Hematology.Biomarker Insights 2007: 2 130
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of oligosaccharides (Fusetti et al. 2003). Crystal 
structures of native YKL-40 and its complex with 
GLcNAc8 showed that YKL-40 binds to oligosac-
charide ligand in a fashion identical to catalytically 
active family 18 chitinases. But in contrast to 
chitinases, in YKL-40 oligosaccharide ligand 
induces large conformational change that might 
have regulatory signiﬁ  cance during host response 
to fungi or nematodes (Houston et al. 2003). 
Although sugar binding was not examined for all 
mammalian chitinase-like proteins, it can be 
predicted that the presence of enzymatically inac-
tive Glyco_18 domain is indicative for lectin 
properties. Currently the enzymatically inactive 
chitinase-like proteins are considered to constitute 
a novel class of cytokines with lectin properties. 
Cell Type Speciﬁ  city 
and Regulation of Expression
The major cell types producing mammalian chitin-
ases and chitinase-like proteins are macrophages, 
neutrophils, epithelial cells, chondrocytes and 
synovial cells, as well as tumor cells (for summary 
see Table 1). Expression of these proteins is regu-
lated on the mRNA level by various cytokines and 
hormones.
Chitotriosidase (CHIT1) and YKL-40 (CHI3L1, 
HC gp-39) were the ﬁ  rst human Glyco_18 containing 
proteins identiﬁ  ed and are the best characterised 
from the biological and clinical points of view. 
The sources of secreted chitotriosidase are 
abnormal lipid-laden macrophages formed in tissues 
of Gaucher disease patients. Gaucher cells can be 
classiﬁ  ed as a variation of alternatively activated 
macrophages; they express CD68, C14, HLA class II, 
CD163, CCL18, and IL-1-receptor antagonist, but do 
not express CD11b, CD40, and proinﬂ  ammatory 
cytokines such as TNFα and MCP1 (Boven et al. 
2004). In vitro, monocyte-derived macrophages start 
to produce chitotriosidase approximately after 7 days 
of culturing (Boot et al. 1999). Production of 
chitotriosidase in cultured macrophages is strongly 
stimulated by GM-CSF (van Eijk et al. 2005). The 
same study demonstrates the inhibitory effect of IFNγ 
and IL-4 on expression of chitotriosidase. At the same 
time several reports indicate the stimulatory effect of 
proinﬂ  ammatory stimuli (IFNγ, TNFα, LPS) on the 
expression of chitotriosidase in monocyte-derived 
macrophages (Di Rosa et al. 2005; Malaguarnera 
et al. 2005). The discrepances might be explained by 
differences in the generation of macrophage cultures 
and can reﬂ  ect the contribution of secondary processes, 
which occur in macrophage cultures. Careful studies 
on the chitotriosidase promoter are required to dissect 
the mechanisms regulating its expression. Two 
enzymatically active isoforms of chitotriosidase, 50 
kDa and 39 kDa were originally puriﬁ  ed out of spleen 
of a Gaucher patient (Renkema et al. 1995). The 39 
kDA isoform lacks C-terminal chitin-binding domain 
and represent a truncated form of the full-size protein 
(Renkema et al. 1997). It is formed during the post-
translational processing. In addition the minor 40-kDa 
isoform is formed as a result of alternative splicing. 
The 50 kDa is the predominantly secreted isoform, 
but all the three isoforms are formed in macrophages 
in vitro and can be detected by proteomics techniques 
in serum of Gaucher patients (Renkema et al. 1997; 
Quintana et al. 2006). In healthy human organism 
mRNA for chitotriosidase was found in lymph nodes, 
lung, and bone marrow, and its expression is restricted 
to the professional phagocytes (Boot et al. 2005b). In 
addition to macrophages, neutrophils were shown to 
be a source of chitotriosidase in human (van Eijk 
et al. 2005). In contrast, mRNA for murine 
chitotriosidase is expressed in the gastrointestinal 
tract, the tongue, fore-stomach and Paneth cells in the 
small intestine (Boot et al. 2005b). 
Both chitotriosidase and YKL-40 were found 
to be markers for activated macrophages in athero-
sclerotic plaque (Boot et al. 1999). Interestingly, 
chitotriosidase and YKL-40 are expressed in 
distinct macrophage subpopulation in atheroscle-
rotic lesions indicating the involvement of differ-
entially polarised macrophages in the progression 
of atherosclerosis. In vitro, the same macrophages, 
which secrete chitotriosidase, can secrete YKL-40 
(Renkema et al. 1998). YKL-40 mRNA was 
detected after 2 days of in vitro cultivation of 
macrophages and reached the maximum at day 14, 
while expression of chitotriosidase started after 7 
days and dramatically increase with time. The 
authors concluded that the expression of YKL-40 
and chitotriosidase is regulated independently. 
YKL-40 is also expressed in human neutrophils, 
which release YKL-40 in inﬂ  ammatory conditions 
(Volck et al. 1998).
YKL-40 was originally isolated as one of the 
major secreted proteins of cultured human articular 
chondrocytes and synovial ﬁ  broblasts (Hakala 
et al. 1993). The name YKL-40 derives from the 
on letter code for the tyrosine, lysine and leucine 
in its N-terminus and its apparent molecular weight 
(Hakala et al. 1993). Later YKL-40 was shown to Biomarker Insights 2007: 2 131
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Table 1. Cell type speciﬁ  city of expression of chitinases and chitinase-like proteins. 
 Chitotriosi  AMCase  YKL-40  YKL-39    SI-CLP  YM-1/2
  dase (CHIT1)  (CHIA)  (CHI3L1)  (CHI3L2)   (CHID1)  (Chi3l3/l4)
Macroph  Mature,     Lung MΦ   MΦ at late  Microglia in M Φ  Microglia in 
ages   monocyte    stages of  AD stimulated  AD
(MΦ) derived  MΦ   differentiation;    with  IL-  murine model
 Gaucher    MΦ stimulated    4/dex; MΦ  of chronic
  cells; lung    with IFNγ;   in  BAL proliferative
 M Φ   tumor      dermatitis;
     -associated     lung
     M Φ; MΦ and      macrophages
      giant cells in      in IL-13-
     pulmonary       transgenic
     sarcoid     mice
     granuloma;     
      subsets of MΦ
     in  the
     atherosclerotic
     plaque;
     Microglia in AD
Neutrophils  PMN of      Non-activated       Neutrophils   
 healthy    and  activated     murine model 
 donors    neutrophils     of CGD
Mast           Murine model   
cells           of chronic
          proliferative
          dermatitis
T-cells         Jurkat  cells,      
         CD3+  cells
         from 
         peripheral
         blood
B-cells         Raji  cells  B-cells in 
          draining lymph
          node of mice
          implanted with
          Brugia malayi
Epithelial cells     Non-       Mucus-
   mucus-       producing
   producing       epithelial cells
   epithelial       of distal airway
   cells of      
   distal      
   airway      
Synovial     Fibroblast-like  Fibroblast-  cells         
cells      synovial cells  like synovial
       cells
Chondrocytes     RA and OA   Articular   
     chondrocytes  cartilage
       chondrocytes
Smooth-       Vascular       
muscle     smooth-muscle
cells     cells  (VSMC)
continuedBiomarker Insights 2007: 2 132
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be a differentiation marker for macrophages, where 
its expression is predominantly regulated by the 
transcription factor SP1 (Rehli et al. 1997, 2003). 
YKL-40 is secreted in vitro by numerous human 
cancer cell lines of different origin, including glio-
blastoma, colon cancer, ovarian cancer, prostate 
cancer, osteosarcoma, malignant melanoma 
(Johansen et al. 2006). In vivo, YKL-40 expression 
was found in places with intensive tissue remodel-
ling. It is not generally synthesised by healthy 
human chondrocytes in vivo, however, mRNA for 
YKL-40 was detected in osteoarthritic cartilage 
(Hakala et al. 1993; Connor et al. 2000). Immuno-
histochemical analysis showed that YKL-40 
protein is expressed in chondrocytes of osteoar-
thritic cartilage mainly in the superﬁ  cial and middle 
zone of the cartilage rather than the deep zone 
(Volck et al. 1999). YKL-40 protein expression 
was detected in biopsies of glioblastomas, breast 
and colon cancer (Nutt et al. 2005; Pelloski et al. 
2005; Johansen et al. 2006).
Various hormones and cytokines regulate the 
production of YKL-40. Studies in IL-6 knockout 
mice reveled that YKL-40 expression depends on 
IL-6 (Johansen et al. 2006). Expression of YKL-40 
mRNA in human monocyte is strongly stimulated 
by IFNγ, and inhibited by IL-4 and dexamethasone 
(Fig. 2 (Kzhyshkowska et al. 2006b)). Proinﬂ  ammatory 
hormones arg-vasopressin (AVP) and parathyroid 
hormone-related protein (PTHrP) differentially 
affect the secretion of YKL-40 by cultured 
chondrocytes (Petersson et al. 2006). Both PTHrP 
and AVP stimulated the secretion of YKL-40 from 
chondrocytes derived from patients with rheumatoid 
arthritis. In contrast AVP decreased and PTHrP did 
not affect the secretion of YKL-40 from chondrocytes 
from patients with osteoarthritis. The chondrocytes 
derived from the healthy subjects showed that AVP 
had an inhibitory effect, whereas the PTHrP did not 
change the amounts of YKL-40.
In contrast to the broad range of YKL-40 
expression, YKL-39 production is predominantly 
demonstrated for chondrocytes and synoviocytes 
(Hu et al. 1996). Comparative quantitative analysis 
using real-time RT-PCR demonstrated that YKL-40 
was strongly upregulated by IFNγ, while YKL-39 
was expressed on a very low level in all macro-
phage subpopulation tested and no speciﬁ  c effects 
of IFNγ, IL-4 or dexamethasone were detected 
(Fig. 2) (Kzhyshkowska et al. 2006b). To our 
knowledge there is only one report showing that 
YKL-39 can be expressed by macrophages. 
Messenger RNAs for both YKL-39 and YKL-40 
were strongly upregulated in the brain of patients 
with Alzheimer’s disease, and this fact was attrib-
uted to the alternative activation of microglial 
macrophage during the course of the disease 
(Colton et al. 2006).
Using Northern blot analysis it was demon-
strated that the second enzymatically active 
mammalian chitinase, AMCase is expressed in 
gastrointestinal tract and to the less extent in the 
lung (Boot et al. 2001). Signiﬁ  cant increase of 
AMCase mRNA and protein was detected in lungs 
of ovalbumin-sensitised mice (aeroallergen asthma 
model) (Zhu et al. 2004). Immunohistochemical 
 Chitotriosi  AMCase  YKL-40  YKL-39    SI-CLP  YM-1/2
  dase (CHIT1)  (CHIA)  (CHI3L1)  (CHI3L2)   (CHID1)  (Chi3l3/l4)
Malignant     Glioblastoma   HEK293,
tumors     (U87);    MCF7,
and tumor      osteosarcoma    HeLa,
cell lines      (MG-63);    A-549
     ovarian  cancer 
     (SW626);
     prostate  cancer
     (DV-145);
     malignant
     melanoma
     (SK-MEL-28);
      cancer cells in
     biopsies  of
     glioblastoma,
     breast  and
     prostate  cancer   
The expression proﬁ  le is described predominantly for human proteins. Expression in mouse cells is indicated in italic.Biomarker Insights 2007: 2 133
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examination showed that the AMCase is expressed 
in both epithelial cells and macrophages in lungs 
of sensitised mice. Expression of AMCase was 
preferentially stimulated by Th2 cytokine IL-13, 
and to much less extent by IL-4, while IL-11 and 
IL-10 did not result in increase of AMCase expres-
sion (Zhu et al. 2004). IL-13 did not induce the 
expression of chitotriosidase in the same model. 
The ability of AMCase to diminish Th2-inﬂ  ammation 
and dependance of this effect on IL-13 receptor 
and STAT6 suggested that the AMCase acts down-
stream of IL-13. In situ hybridisation with human 
AMCase probes showed that the AMCase mRNA 
is induced in both epithelial cells and subepithelial 
cells (probably macrophages) in lung tissues of 
asthmatic patients (Zhu et al. 2004).
YM1 and YM2 were found only in rodents and 
have no human analogue neither on genomic nor on 
protein level (Chang et al. 2001; Raes et al. 2005). 
YM1 is predominantly produced by macrophages 
(Chang et al. 2001; Welch et al. 2002; Nair et al. 2003, 
2005). In murine models of Th2-type parasite infec-
tions, expression of both YM-1 and AMCase depends 
on the activity of IL-21 receptor, which has structural 
homology to IL-4Rα chain and responds to the Th2 
cytokine IL-21 (Pesce et al. 2006).
Since both YM1 and AMCase are induced in Th2-
environment, several researchers consider human 
AMCase to be a functional homologue of murine 
YM1. However, both absence of chitin-binding 
domain and catalytic aminoacids within Glyco_18 
domain of YM1 (see Fig. 1) argue against this point 
of view (Boot et al. 2005a). Moreover in murine 
experimental model of asthma, YM1 and AMCase 
were shown to be useful markers for distinguishing 
between proximal and distal airway epithelium. 
AMCase is expressed by non-mucus-producing 
CCSP-expressing cells of the distal airway, and YM-
1 is expressed by the mucus-producing cells of the 
proximal airways (Homer et al. 2006).
We have recently demonstrated that the human 
macrophages produce one more catalytically inac-
tive Glyco_18 domain-containing protein, SI-CLP 
(stabilin-1 interacting chitinase-like protein) 
Figure 2. Real-time RT-PCR analysis of SI-CLP and YKL-40 expression in human macrophages. Peripheral blood derived monocytes 
non-stimulated (control) or stimulated with cytokines as indicated were propagated in culture for 6 days. Three representative donors with 
differential responsivities are presented. (A) IL-4, dexamethasone and combination of both induce SI-CLP mRNA upregulation in macrophage 
cultures, the lowest SI-CLP expression is detected in case of IFNγ stimulation. (B) IFNγ induces YKL-40 mRNA expression, whereas 
dexamethasone has strong inhibitory effect (Kzhyshkowska et al. 2006).  This research was originally published in Blood. Kzhyshkowska, 
J et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via 
lysosomal pathway Blood. 2006; 107:3221-3228. © the American Society of Hematology.Biomarker Insights 2007: 2 134
Kzhyshkowska et al
(Kzhyshkowska et al. 2006b). The expression of 
SI-CLP is induced by Th2 cytokine IL-4 and gluco-
corticoid dexamethasone (Fig. 2). Combined IL-
4/dexamethasone stimulation has a synergistic 
effect and is impaired in the presence of prototype 
Th1 cytokine IFNγ. In vivo, high amounts of SI-
CLP were detected in macrophages from bron-
choalveolar lavage of patients with chronic airway 
inﬂ  ammation. SI-CLP protein expression is not 
restricted to primary macrophages and is found in 
Raji cells, Jurkat cells, various tumor cell lines 
(Kzhyshkowska et al. 2006b), as well as in CD3 + 
T-cells, isolated from peripheral blood of healthy 
donors (Kzhyshkowska, unpublished data). 
However, until now the secretion of SI-CLP was 
shown only for IL-4-stimulated macrophages 
(Kzhyshkowska et al. 2006b).
The most distant member of human Glyco_18 
domain-containing proteins, oviductin (mucin 9, 
MUC9; oviduct-speciﬁ  c glycoprotein, OGP) is 
exclusively expressed and secreted by oviductal 
epithelium (Malette et al. 1995; Arias et al. 1994; 
Lagow et al. 1999). Estradiol and luteinizing 
hormone both have a stimulatory effect on 
oviductin mRNA in fertile women. However, indi-
vidual contribution of these stimulations was 
difﬁ  cult to determine since the luteinizing hormone 
surge is dependent on the estradiol increase. In the 
same study progesterone was shown to have a clear 
inhibitory effect on oviductin mRNA expression 
(Briton-Jones et al. 2001). Direct stimulatory effect 
of estradiol-17 β was demonstrated for the murine 
oviductin promoter (Takahashi et al. 2000).
Intracellular Sorting and Modes 
of Secretion
Up to date two types of vesicles were demonstrated 
to secrete chitinases and chitinase-like proteins: 
lysosomes in macrophages and secretory granula 
in neutrophils.
Intracellular localisation studies demonstrated that 
the chitotriosidase and SI-CLP are primarily localised 
in lysosomes in macrophages (Renkema et al. 1997; 
Kzhyshkowska et al. 2006b). Besides the classical, 
constitutively operating ER/Golgi secretory pathway, 
which is primarily regulated on the level of gene 
expression, macrophages use non-classical (Nickel, 
2003) and lysosomal secretory pathways (Andrews, 
2000; Stinchcombe and Grifﬁ  ths, 1999). The lyso-
somal secretion route in macrophages is regulated by 
speciﬁ  c sorting of newly synthesised products into 
secretory lysosomes (Logan et al. 2003). Constitutive 
delivery of lysosomal enzymes to the lysosomes is 
ubiquitously mediated by mannose-phosphate recep-
tors CI-MPR and CD-MPR (Ghosh et al. 2003; Korn-
feld and Mellman, 1989; Kornfeld, 1986). However, 
Glyco_18 domain-containing proteins differ from 
other lysosomal enzymes by the lack of N-glycosyl-
ation typical of lysosomal enzymes and necessary for 
the recognition by MPRs (Renkema et al. 1997; Boot 
et al. 2001). Thus, lysosomal routing of Glyco_18 
containing proteins can differ from the classical MPR-
mediated one. We have recently demonstrated that the 
intracellular sorting of SI-CLP in alternatively activated 
macrophages is mediated by the scavenger receptor 
stabilin-1. (Kzhyshkowska et al. 2006b) SI-CLP is 
recognised by stabilin-1 in trans-Golgi network and 
delivered to the late endosomes and consequently into 
Lamp1-positive and secretion-committed CD63-posi-
tive lysosomes. It is currently unknown whether the 
stabilin-1 can mediate lysosomal routing of other than 
SI-CLP chitinase-like proteins, and which other intra-
cellular receptors can be involved in this process. 
Synthesis, processing and intracellular sorting of 
human chitotriosidase was examined in details in 
primary monocyte derived macrophages, which were 
differentiated in culture in the absence of Th1 or Th2 
cytokines (Renkema et al. 1997). Immunoelectron 
microscopy and subcellular fractionation demon-
strated that chitotriosidase is sorted into lysosomes. 
Chitotriosidase was detected in lysosomal vesicles 
comparably to cathepsin D, and chitotriosidase 
activity was found in fractions positive for lysosomal 
enzyme β-hexoaminidase. Chitotriosidase was shown 
to be synthesised as a 50 kDa protein and partially 
processed resulting in a 39 kDa form. The 39-kDa 
isoform was predominantly found in dense core frac-
tions of mature lysosomes, while the 50-kDa form 
was found in fractions of lower density, which were 
considered by the authors to contain pre-lysosomal 
compartment (Renkema et al. 1997). However, it can 
be also hypothesised that the 50-kDa form was sorted 
into a distinct subpopulation of secretory-committed 
lysosomes. In the bloodstream, the 50 kDa isoform 
was predominant, while the 39-kDa isoform was 
abundant in the tissues (Renkema et al. 1997).
Peripheral blood monocytes differentiated in 
culture into mature macrophages secrete both 
chitotriosidase and YKL-40 (Renkema et al. 1998). 
However, no intracellular localisation studies were 
performed up to date to deﬁ  ne whether YKL-40 
and chitotriosidase are sorted into the same vesicles 
in macrophages.Biomarker Insights 2007: 2 135
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In neutrophils, both the chitotriosidase and 
YKL-40 are sorted into speciﬁ  c granules (Volck 
et al. 1998; Nordenbaek et al. 1999; van Eijk et al. 
2005). Differential induction of lysosomal or secre-
tory granula secretion in polymorphonuclear 
neutrophils (PMN) demonstrated that chitotriosi-
dase is not sorted into lysosome-like azurophilic 
granules. Using immunogold double labelling 
experiments, chitotriosidase was detected in 
speciﬁ  c lactoferrin-containing granules in PMN 
(van Eijk et al. 2005). YKL-40 also co-localises 
with lactoferrin, but not with gelatinase in both 
stimulated and non-stimulated neutrophils. It is 
suggested that neutrophil-released YKL-40 acts as 
an autoantigen in rheumatoid arthritis (RA). More-
over, release of YKL-40 from speciﬁ  c neutrophil 
granules was suggested to lead to the post-trans-
fusional complications and can be prevented by 
the pre-storage leukocyte depletion by ﬁ  ltration of 
whole blood (Cintin et al. 2001). 
The current picture of the intracellular localisa-
tion and regulation of chitinase and chitinase-like 
proteins is far from being complete. Particularly, 
it is not known, whether these proteins are sorted 
into a speciﬁ  c subclass of lysosomes in macro-
phages, and whether there is a mechanism for the 
selective secretion of these lysosomes. As well, the 
mechanism of secretion of chitinase and chitinase-
like proteins from cells of non-myeloid origin, like 
ﬁ  broblasts and epithelial cells was not studied. 
Glyco_18 Containing Proteins 
in Human Disorders
Mammalian chitinases and chitinase-like proteins 
are secreted into extracellular space in tissues and 
blood circulation. They possess numerous of cell 
physiological and immunomodulatory activities 
(Table 2). Accumulating data point toward connec-
tion of their biological activities with various 
Table 2. Chitinases and chitinase-like proteins: biological activity.
  Enzymatic   Proliferative  Effect on cell  Immunomodulatory 
 activity  effect  adhesion  and  effect
    migration
Chitotriosidase Hydrolytic  and   
  trans-
 glycosylation
 activity
AMCase  Hydrolytic      Regulation of IL-13
  activity      downstream effect in
      asthma
YKL-40  No  Growth-  Migration,  In healthy donors:
  promoting  spreading  and  induction  of  IL-10
    effect on  attachment of  production in monocytes
    human  VSMC  and T-reg; in RA patient:
  synovial    induction  of  Th1  immune
  cells,  skin    response;
  and  foetal    suppression  the  TNFα
  lung    and  IL-1-induced
  ﬁ  broblasts    secretion of MMPs and
        IL-8 in human skin
      ﬁ  broblasts and articular
      chondrocytes
YKL-39  No      Induction of autoimmune  
        processes (Sakata et al.  
        2002; Tsuruha et al.   
      2002)
YM1/YM2 No    Chemotaxis  for 
    eosinophils,  T-cells, 
    polymorphonuclear 
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human diseases. Already established association 
of mammalian Glyco_18 domain-containing 
proteins with various human disorders is 
summarised in Table 3.
Chitotriosidase
Chitotriosidase (ChT), is a human analogue of 
chitinases from non-vertebrate species that serves 
both as a diagnostic hallmark of Gaucher disease 
(GD, glucosylceramidosis), and as a marker for 
monitoring the efﬁ  cacy of various therapeutic 
approaches for treatment of GD (Hollak et al. 
1994, 2001; de Fost et al. 2006; Pastores and 
Barnett, 2005; Pastores et al. 2005). Gaucher 
disease is caused by recessively inherited deﬁ  -
ciency in activity of lysosomal hydrolase—gluco-
cerebrosidase, and is characterised by accumula-
tion of glucosylceramide (glucocerebroside) in the 
lysosomes of macrophages (Bussink et al. 2006). 
This process is restricted to tissue macrophages 
that transform into large swollen lipid-laden 
Gaucher cells. Pathological consequences of the 
accumulation of lipid-laden macrophages include 
hepatosplenomegaly, bone lesions, and less 
frequently neurological abnormalities. Limited 
correlation between genotype and phenotype of 
the GD, as well as highly expensive enzyme 
supplementation therapy indicated the necessity 
of easily identiﬁ  able biomarker for the GD. In 
1994, Hollak et al. reported, that the median 
activity of chitotriosidase in plasma samples of 
GD patients is more than 600 times higher in 
comparison to control subjects (Hollak et al. 
1994). Activity of chitotriosidase in plasma is a 
surrogate marker for the tissue Gaucher cells. 
Accurate monitoring of chitotriosidase is performed 
by determination of hydrolytic activity towards 
ﬂ  uorogenic chitooligosacharide substrates that has 
been improved recently (Aguilera et al. 2003). 
Proteomics approach demonstrated the possibility 
for the quantitative imaging of various chitotrio-
sidase isoforms (Quintana et al. 2006). Plasma 
chitotriosidase activity strongly correlated with 
Table 3. Chitinases and chitinase-like proteins: association with disorders.
 Infectious  Lysosomal  Chronic  Allergy  Cancer  Liver    Neurode
 diseases  storage    inﬂ  ammation      disorders  generative
   diseases         diseases
Chitotriosi Fungal  and, Gaucher  Atheroscler      Non-  Alzheimer’s 
dase bacterial;    disease; osis;      alcoholic  disease;
 malaria  Niemann-  sarcoidosis      fatty  liver  ischemic 
    Pick disease;        disease –   cerebro
    Fabry          steatohep  vascular
   disease        atitis    dementia
          (NASH) 
AMCase       Asthma    
YKL-40 Pneumonia;    Atheroscler   Diagnostic HCV-
  purulent     osis;    and progn  induced
 meningitis;    rheumatoid    osticmarker    liver  ﬁ  brosis
  Escherichia     arthritis;    for number of  and cirrhosis, 
  coli endoto    sarcoidosis;    solid tumors  ﬁ  brosis in 
 xaemia    inﬂ  ammatory      alcoholics   
     bowel  disease      
YKL-39     Osteoarthritis;      
     rheumatoid        
     arthritis      
SI-CLP       Th2-induced 
       pathologies      
       suggested
YM1/YM2 Parasite   
  infections           
 in  rodentsBiomarker Insights 2007: 2 137
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integrated intensities of chitotriosidase isoforms. 
But no methods are available at the moment for 
the assessment of individual contribution of each 
chitotriosidase isoform in total activity. Compar-
ison of chitotriosidase activity in urine and plasma 
of GD patients demonstrated that the enzyme 
activity in urine does not correlate well with the 
plasma values. The authors suggested that the 
urinary chitotriosidase reﬂ  ects the renal pathology 
rather than Gaucher cell activity. In sharp contrast 
to chitotriosidase, the levels of chemokine CCL18 
both in plasma and in urine correlated perfectly 
with other GD values. Taking under consideration 
the existence of recessively inherited deﬁ  ciency 
in chitotriosidase with an incidence of about 6% 
in Caucasian (Boot et al. 1998), CCL18 can be 
used as an alternative biomarker for enzyme-deﬁ  -
cient GD patients (Boot et al. 2004,2006; Deegan 
et al. 2005). 
Degree of chitotriosidase activity in plasma can 
be also applied for the evaluation of likelihood of 
lysosomal storage disorders other than GD (Guo 
et al. 1995; Ries et al. 2006; Wajner et al. 2004; 
Aerts et al. 2005). The examination of chitotriosi-
dase activity provides useful information for the 
selection of further conﬁ  rmatory assays for sphin-
gomyelinase deficiency (SMD, Niemann-Pick 
disease type A/B) and Niemann-Pick disease type 
C (NPC) (Ries et al. 2006). Chitotriosidase is the 
only biomarker identiﬁ  ed up to date for the moni-
toring of lipid-laden macrophages and the efﬁ  cacy 
of enzyme-replacement therapy in male Fabry 
patients. Fabry disease is a X-linked globotriao-
sylceramidosis caused by the deﬁ  ciency in the 
lysosomal α-galactosidase A (AGA) (Vedder et al. 
2006). Plasma chitotriosidase can be detected in 
very young age, precedes clinical manifestations 
and is elevated constituently with the accumulation 
of lipid-laden macrophages in tissues. Therapy 
with recombinant AGA results in normalisation of 
plasma chitotriosidase levels (Vedder et al. 2006). 
Comparable with GD patients elevation of chitot-
riosidase activity was demonstrated in plasma of 
patients with β-thalassemia, a haematological 
disorder caused by genetic defect of the synthesis 
of β-globin chains leading to unproductive eryth-
ropoiesis and enormous expansion of reticuloen-
dothelial system (Barone et al. 1999; Altarescu 
et al. 2002). It was proposed that iron-mediated 
damage of lysosomal system and macrophage 
activation may result in increased secretion of 
chitotriosidase (Barone et al. 1999).
Expression of chitotriosidase mRNA is induced 
in patients with non-alcoholic fatty liver disease 
—steatohepatitis (NASH) (Malaguarnera et al. 
2006a). NASH comprises a wide spectrum of liver 
damages ranging from uncomplicated steatosis to 
advanced ﬁ  brosis and cirrhosis. NASH can occur, 
for example, in association with use of drugs, 
surgical interventions, and metabolic disorders 
(Malaguarnera et al. 2006b). Using fractionation 
of liver cells the authors demonstrated that over-
production of chitotriosidase occurs solely in 
Kupffer cells (liver macrophages). Overproduction 
of chitotriosidase resulted in the activation of 
hepatic stellate cell, suggesting the role of this 
conservative enzyme in the progression of hepatic 
ﬁ  brosis (Malaguarnera et al. 2006a, 2006b).
Elevated expression of chitotriosidase mRNA was 
detected in Alzheimer’s disease (AD), and was even 
more pronounced in Ischemic cerebrovascular 
dementia (CvD) (Di Rosa et al. 2006). AD is a progres-
sive neurodegenerative disorder, characterised by the 
formation of senile plaque composed of insoluble β-
amiloid ﬁ  bril deposits, astrocytes and degenerating 
neurons. Pathophysiology of CvD includes the devel-
opment of brain ischemia and multi-infarct cognitive 
impairment. Despite the heterogenous nature, there 
are common inﬂ  ammatory processes, i.e. activation 
microglia and T-cell immunity, occurring during the 
progress of AD and CvD. Induction of chitotriosidase 
gene expression in parallel with other cytokines is a 
marker for the inﬂ  ammatory processes during the 
neurodegenerative disorders. Moreover, chitotriosi-
dase was reported to be a speciﬁ  c marker for macro-
phage activation occurring in stroke. Chitotriosidase 
activity correlates with stroke severity independently 
on preexisting inﬂ  ammatory or infectious conditions 
(Sotgiu et al. 2005). The role of this enzyme in the 
pathology of brain has to be further investigated. 
Elevated levels of serum chitotriosidase were 
also found in disorders caused by the abnormal 
activation of immune system, including sarcoidosis 
(Grosso et al. 2004) and atherosclerosis (Boot 
et al. 1999; Artieda et al. 2003). In atherosclerosis, 
chitotriosidase is produced by subsets of macro-
phages in atherosclerotic plaque, and enzyme 
activity is elevated up to 55-fold in extracts of 
atherosclerotic tissue. It is hypothesised that the 
chitotriosidase together with YKL-40 regulate cell 
migration and tissue remodelling during athero-
genesis (Boot et al. 1999).
Human chitotriosidase also associates with 
pathogen-driven diseases, and in particular with fungal Biomarker Insights 2007: 2 138
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infections, suggesting the role of this enzyme in host-
defence against chitin-containing pathogens 
(Labadaridis et al. 1998, 2005). Thus, the elevated 
level of chitotriosidase activity was detected in plasma 
and/or urine of neonates with fungal infection 
(Labadaridis et al. 2005). Increased activity of chito-
triosidase was also found in neonates with bacterial 
infections, suggesting that it is rather an indicator of 
macrophage activity during the course of infectious 
diseases, but not a speciﬁ  c anti-fungal response. The 
authors proposed that the identiﬁ  cation of an increased 
level of chitotriosidase activity can be used as an 
indicator for possible fungal infection if the bacterial 
infection is absent. Furthermore, serial urine analysis 
can be useful for the monitoring of the efﬁ  ciency of 
anti-fungal therapy in neonates (Labadaridis 
et al. 2005). Demonstrated by van Eijk et al. anti-
fungal activity of human chitotriosidase both in vitro 
and in the animal model, indicates its role as an innate 
immunity component in host response against chitin-
containing pathogens (van Eijk et al. 2005).
Plasma chitotriosidase activity is increased in 
African children with acute Plasmodium falciparum 
malaria and correlates with other disease parameters 
(Barone et al. 2003). The levels of chitotriosidase 
were found to be higher in African patients than in 
Caucasian population. Interestingly, signiﬁ  cant corre-
lation was found between plasma chitotriosidase and 
reticulo-endothelial activation, as judged by throm-
bocytopenia degree and serum ferritin level in children 
with acute malaria.
Thus, the chitotriosidase is indicator for macro-
phage-driven inﬂ  ammatory processes in various 
organs. Its role as an innate immune component in 
anti-fungal response has to be further conﬁ  rmed. 
Chitotriosidase remains to be the main biomarker 
for the diagnostic and evaluation of therapeutic 
approaches in GD; however, the additional 
improvement can be achieved by the parallel use 
of other markers, like, for example, CCL18. 
YKL-40
YKL-40, also called human cartilage glycoprotein-
39 (HC gp-39), is the best investigated human 
chitinase-like protein regarding its biological 
activity and association with various disorders. 
Two comprehensive reviews have been published 
recently which elucidate in details association of 
YKL-40 with human disorders, methods of YKL-
40 detection and evaluation of YKL-40 as a diag-
nostic and prognostic factor (Johansen et al. 2006; 
Rathcke and Vestergaard, 2006). Here, we discuss 
only the most important biological functions of 
YKL-40 and briefly summarise major YKL-
40- associated pathologies.
 Biological activities of YKL-40 include regula-
tion of cell proliferation, adhesion, migration and 
activation. YKL-40 promotes the growth of human 
synovial cells, skin and foetal lung ﬁ  broblasts. The 
proliferative effect of YKL-40 synergizes with the 
effect of insulin-like growth factor-1 (Recklies et al. 
2002). At the same time YKL-40 is able to suppress 
the TNFα and IL-1-induced secretion of matrix 
metalloproteases and IL-8 in both human skin ﬁ  bro-
blasts and articular chondrocytes. Thus, YKL-40 
promotes the proliferation and antagonizes catabolic 
or degradative processes during the inﬂ  ammatory 
response of connective tissues (Ling and Recklies, 
2004). Cg-Clp1, the conserved molluscan homo-
logue of YKL-40, stimulates proliferation and 
regulates synthesis of extracellular matrix compo-
nents in rabbit articular chondrocytes (Badariotti 
et al. 2006). Recently, the existence of three isoforms 
YKL-40 was reported: a major and minor forms 
from resorbing cartilage and a third specie from 
chondrocytes (Bigg et al. 2006). Afﬁ  nity chroma-
tography experiments with puriﬁ  ed YKL-40 demon-
strated speciﬁ  c binding of all three isoforms to 
collagens types I, II, and III. The chondrocyte-
derived YKL-40 isoform was able to prevent 
collagenolytic cleavage of type I collagen and to 
stimulate the rate of type I collagen ﬁ  bril formation. 
By contrast, the cartilage major form had an inhib-
itory effect on type I collagen ﬁ  brillogenesis. Differ-
ential modulatory effect of various YKL-40 
isoforms indicates that expression of specific 
isoforms has to be taken into consideration in the 
epidemiological and functional studies. 
YKL-40 has also cell-type speciﬁ  c effect on cell 
migration. It induces the migration of vascular smooth 
muscle cells (VSMC), but not ﬁ  broblasts. Moreover, 
YKL-40 promotes the attachment and spreading of 
VSMC (Nishikawa and Millis, 2003). The ability of 
YKL-40 to regulate cell proliferation, adhesion, 
migration, and activation, as well as to regulate extra-
cellular matrix assembly, correlates well with elevated 
level of YKL-40 in the sites of chronic inﬂ  ammation 
and active connective tissue turnover. 
Circulating YKL-40 can be detected by non-inva-
sive methods in human serum or plasma using in-
house RIA (Johansen et al. 1993, 2006) as well as 
by commercially available ELISA (Quidel, Santa 
Clara, CA (Harvey et al. 1998). Increased concentra-Biomarker Insights 2007: 2 139
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tions of YKL-40 were detected not only in sites of 
inﬂ  ammation, but also in serum of patients with 
rheumatoid arthritis (RA). In RA, YKL-40 acts as 
an autoantigen. In contrast to healthy individuals, 
who show strong bias to regulatory response to YKL-
40, 50% of patients with RA exhibit polarisation 
towards Th1 phenotype (van Bilsen et al. 2004). 
Local release of YKL-40 in the arthritic joint is 
followed by a secondary increase of YKL-40 concen-
tration in serum. Several independent groups demon-
strated that the elevated levels of YKL-40 in serum 
reﬂ  ect the degree of the synovial inﬂ  ammation and 
joint destruction in patients with RA and OA 
(Johansen et al. 1999, 2001; Matsumoto and Tsuru-
moto, 2001; Peltomaa et al. 2001; Conrozier et al. 
2000). Rheumatic symptoms are also common for 
extra-intestinal manifestations of inflammatory 
bowel disease (IBL), and elevated level of YKL-40 
is a marker for joint involvement in IBL (Bernardi 
et al. 2003) and for the activity of the disease (Vind 
et al. 2003).
YKL-40 is expressed in human smooth muscle 
cells and upregulated in distinct subsets of macro-
phages in the atherosclerotic plaque. Expression of 
YKL-40 mRNA was higher in macrophages in early 
atherosclerotic lesions and in macrophages which 
inﬁ  ltrated deep in the lesion and (Boot et al. 1999). 
YKL-40 is a vascular cell adhesion and migration 
factor that may have a role in processes leading to 
vascular occlusion and heart development 
(Nishikawa and Millis, 2003). In concentration of 
1 ng/ml YKL-40 has a profound effect on migration 
of vascular smooth muscle cell (VSMC), but not on 
migration of fibroblasts. In addition YKL-40 
promotes VSMC attachment and spreading. 
Proteomics study identiﬁ  ed elevated levels of YKL-
40 in supernatants of macrophage cell line THP-1 
treated with oxidised LDL (in vitro “foam cell“ 
model) (Fach et al. 2004). Consequently, YKL-40 
expression is indicative for the differentiation of 
macrophages during formation of atherosclerotic 
plaque (Rathcke and Vestergaard, 2006). Most 
recently, elevated levels of YKL-40 were found in 
patients with type 2 diabetes, where YKL-40 posi-
tively correlates with insulin resistance and with 
features of dyslipidaemia. Both YKL-40 and hsCRP 
were found to be related to insulin resistance in 
patients with T2D; however, the increase of plasma 
concentrations of YKL-40 and hsCRP occurred 
independently (Rathcke et al. 2006). In contrast, in 
rheumatoid arthritis the serum levels of YKL-40 
positively correlated with serum levels of IL-6 and 
CRP. YKL-40 was suggested to be an independent 
biomarker for the inflammatory/atherosclerotic 
processes in T2D patients (Rathcke and Vestergaard, 
2006; Rathcke et al. 2006). 
YKL-40 was also found to be associated with 
another disease characterised by chronic inﬂ  am-
mation, i.e. pulmonary sarcoidosis. Both macro-
phages and giant cells in pulmonary sarcoid 
granuloma express YKL-40, and serum levels of 
YKL-40 are indicative for sarcoid disease activity 
and ongoing ﬁ  brosis (Johansen et al. 2005b).
Serum levels of YKL-40 are elevated in patients 
with pathogen-induced inﬂ  ammation, including 
purulent meningitis, pneumonia and endotoxaemia 
caused by endotoxin of. Escherichia coli. (Osterg-
aard et al. 2002; Nordenbaek et al. 1999; Kronborg 
et al. 2002; Johansen et al. 2005a; Rathcke and 
Vestergaard, 2006). In both meningitis and pneu-
monia, YKL-40 is secreted by locally activated 
macrophages (Ostergaard et al. 2002) and 
neutrophils (Nordenbaek et al. 1999), and was 
proposed as a speciﬁ  c supplementary serological 
marker for the activation of granulocytes and 
macrophages in inﬂ  amed tissues (Rathcke and 
Vestergaard, 2006).
Increased production of YKL-40 is indication for 
liver pathology. YKL-40 is differentially upregu-
lated in cirrhotic liver on the end-stage of hepatitis 
C virus (HCV) induced liver cirrhosis (Shackel 
et al. 2003). Serum level of YKL-40 correlates with 
YKL-40 mRNA expression in liver (Kamal et al. 
2006), and was suggested to be a useful non-invasive 
marker for evaluation of the degree of ﬁ  brosis as 
well as efﬁ  ciency of therapy in patients with HCV-
associated liver disorders (Saitou et al. 2005). 
Increased plasma levels of YKL-40 were also 
suggested to reﬂ  ect the progression of liver ﬁ  brosis 
in alcoholics (Tran et al. 2000).
Elevated level of YKL-40 in the circulation was 
found in number of solid tumors including breast 
cancer, colorectal cancer, ovarian cancer, glioblas-
toma, metastatic renal and prostate cancer and 
malignant melanoma (Johansen et al. 2006). Serum 
levels of YKL-40 are indicative for the poor prog-
nosis and efﬁ  ciency of metastatic process. For 
example, serum level of YKL-40 is an independent 
marker for the aggressiveness of metastatic breast 
cancer (Jensen et al. 2003). Increased plasma 
concentration of YKL-40 is related to poor prog-
nosis and shorter survival in patients with ovarian 
cancer (Hogdall et al. 2003), colorectal carcinoma 
(Cintin et al. 2002), metastatic prostate carcinoma Biomarker Insights 2007: 2 140
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(Brasso et al. 2006), and melanoma (Schmidt 
et al. 2006a, 2006b). YKL-40 was recently 
proposed as a novel marker for the detection of 
endometrial cancer (Diefenbach et al. 2006). 
However, in most solid tumors, the serum concen-
trations of YKL-40 do not show high sensitivity 
for identiﬁ  cation of primary cancer, and determina-
tion of YKL-40 cannot be used as a single screening 
marker for diagnosis of cancer (Johansen et al. 
2006). In addition there is no direct correlation 
between the expression level of YKL-40 and 
various tumor antigens (Brasso et al. 2006). Out 
of six necessary criteria of “tumor marker utility 
system” (Hayes et al. 1996; Hayes 1998), YKL-40 
is positive only for three, and therefore is currently 
considered to be investigational (Johansen et al. 
2006). It is suggested that differential expression 
of YKL-40 reﬂ  ects difference in biology of cancer 
cells which produce YKL-40 or do not produce 
YKL-40 (Johansen et al. 2006). 
However, it is still questionable which cell 
populations or their combinations are critical for 
the secretion of YKL-40 in human malignancies. 
In particular, it is not known, whether tumor cells 
or tumor-associated macrophages are responsible 
for the elevation of serum levels of YKL-40 during 
cancer progression. Thus, the elevated levels of 
YKL-40 can reﬂ  ect integrated effect of cancer cell 
activity and activation status of tumor-associated 
macrophages.
YKL-39
YKL-39 is currently recognised as a biochemical 
marker for the activation of chondrocytes and the 
progress of the osteoarthritis in human that is more 
accurate than YKL-40 (Knorr et al. 2003).
YKL-39 was identified as an abundantly 
secreted protein in primary culture of human 
articular chondrocytes (Hu et al. 1996). N-Terminal 
sequencing of YKL-40 containing fraction of 
conditioned medium revealed the presence of a 
second closely related protein. In case of YKL-40 
the sequence was YKLVCYYTSWSQYR while in 
case of YKL-39 the sequence was YKLVCYFT-
NWSQDR. Since the new protein also had a YKL 
motif, it was called YKL-39 in accordance with its 
apparent molecular weight (MW). In contrast to 
YKL-40, YKL-39 is not a glycoprotein. Although 
the predicted number of aminoacids was slightly 
larger in YKL-39, the presence of carbohydrate in 
YKL-40, but not YKL-39 explained the differences 
in MW (Hu et al. 1996). YKL-39 accounted for 4% 
and YKL-40 for 33% of the secreted protein in 
chondrocyte-conditioned medium. Despite of the 
high homology on the protein level (more than 
50%), the radioimmunoassay developed for the 
detection of YKL-40 in serum in tissues, was 
shown to be very speciﬁ  c and does not detect YKL-
39 (Hu et al. 1996). 
Comparison of the expression of YKL-39 and 
YKL-40 in osteoarthritic cartilage revealed that 
YKL-39 mRNA is significantly upregulated in 
cartilage of patients with osteoarthritis versus 
normal subjects. Increased expression of YKL-39 
mRNA correlated with the upregulation of collagen 
2; while YKL-40 mRNA showed no signiﬁ  cant 
upregulation in OA cartilage (Steck et al. 2002). 
Another study showed that the normal human chon-
drocytes express mRNA for both YKL-39 and 
YKL-40. However, while the expression of YKL-39 
was upregulated both in early degenerative and late 
stage osteoarthritis, the expression of YKL-40 was 
downregulated during the progression of osteoar-
thritis (Knorr et al. 2003). Proteomic analysis iden-
tiﬁ  ed YKL-39, but not YKL-40 to be secreted by 
human osteoarthritic cartilage in culture (De Ceun-
inck et al. 2005). Thus, the elevation of YKL-40 in 
serum and synovial ﬂ  uid of patients with arthritis 
might result from its overproduction by synovial 
cell and macrophages, but not by chondrocytes. 
Two biological activities of YKL-39 might 
contribute to the disease progression. One is the induc-
tion of autoimmune response (Sekine et al. 2001; 
Tsuruha et al. 2002; Du et al. 2005), and second is the 
participation in tissue remodelling. Immunisation with 
puriﬁ  ed YKL-39 induced arthritis in different strains 
of mice (Sakata et al. 2002). Histological examination 
revealed synovial proliferation and irregularity of the 
cartilage surface in BALB/c mice. After injection of 
puriﬁ  ed YKL-39, not only anti-YKL-39 antibody was 
detected, but also the antibody against type II collagen, 
suggesting the spreading of autoimmune reactions 
(Sakata et al. 2002). This animal model suggested that 
the role of YKL-39 as an inducer of autoimmune 
processes related to arthritis. Antibodies to YKL-39 
can be detected in human serum with ELISA and 
Western blotting, and were found in patients with 
rheumatoid arthritis (RA) and osteoarthritis (OA) 
(Sekine et al. 2001; Du et al. 2005; Tsuruha et al. 
2002). Autoantibodies to YKL-39 were detected in 
8–11.8% (Sekine et al. 2001; Tsuruha et al. 2002) of 
patients with RA, and in 11.1% (Tsuruha et al. 2002) 
of patients with OA, while only 1% of patients with Biomarker Insights 2007: 2 141
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RA had autoantibodies to YKL-40 (Sekine et al. 
2001). The immune response to YKL-39 was inde-
pendent of that to YKL-40 (Sekine et al. 2001). In 
patients with OA, the prevalence of autoantibodies to 
YKL-39 and other autoantigens on early stages of 
disease suggested that the autoimmune response 
occurs during the initial phase of cartilage degenera-
tion (Du et al. 2005). Participation of YKL-39 in tissue 
remodelling was suggested on the basis of its high 
level in chondrocyte cultures and close homology to 
YKL-40 that was shown to induce cell proliferation 
and migration. However, the biological activity of 
YKL-39 remains to be identiﬁ  ed.
AMCase
Overproduction of enzymatically active AMCase 
was recently linked to asthma development (Elias 
et al. 2005; Zhu et al. 2004). Asthma is a chronic 
disease characterised by exaggerated Th2 airway 
inﬂ  ammation (Ray and Cohn, 1999). Mouse model 
of ovalbumin-induced bronchial asthma has shown 
that the acid mammalian chitinase (AMCase) is 
involved in the pathophysiology of asthma and acts 
downstream of interleukin-13. Administration of 
anti-AMCase antibody leads to a decrease of Th2-
inﬂ  ammation, tissue eosinophilia and lymphocyte 
accumulation (Zhu et al. 2004). Similar effects were 
detected after the application of chitinase inhibitor 
allosamidin. Thus, the enzymatic activity of 
AMCase was suggested to be involved in asthma 
progression. Search for common genetic variants of 
human AMCase in pediatric asthma, revealed that 
both polymorphisms and haplotypes of AMCase are 
associated with bronchial asthma in children (Bier-
baum et al. 2005). In murine models, AMCase was 
found to be a feature of anti-parasite responses. 
Thus, the ﬁ  nding that AMCase contributes both to 
the host anti-parasite response and asthmatic Th2-
inﬂ  ammation supports the concept that asthma is an 
abnormal anti-parasite response in the absence of 
the pathogen (Elias et al. 2005).
SI-CLP
SI-CLP (stabilin-interacting chitinase-like proteins) 
is the most recent identiﬁ  ed human Glyco_18 
domain-containing protein (Kzhyshkowska et al. 
2006b). It was found as an interacting partner and 
sorting ligand for the multifunctional receptor 
stabilin-1, which is specifically expressed on 
subpopulations of tissue macrophages and sinu-
soidal endothelial cells in liver, spleen, lymph node 
and bone marrow (Kzhyshkowska et al. 2006a, 
2005, 2006c Martens et al. 2006). In parallel with 
stabilin-1, expression of SI-CLP mRNA was 
strongly upregulated in macrophages by the Th2 
cytokine IL-4 and by dexamethasone. We devel-
oped rat monoclonal antibody 1C11 recognising 
N-terminal epitope in SI-CLP. This epitope is 
located upstream of conservative Glyco_18 domain 
and has no similarity with sequences of other 
human Glyco_18 containing proteins. Using the 
1C11 antibody we demonstrated that IL-4 and 
dexamethasone in combination increase SI-CLP 
protein levels in macrophages, the extent of which 
varied between donors. Further, we found that 
macrophages treated with IL-4 secrete SI-CLP, 
while co-stimulation with dexamethasone blocked 
secretion and resulted in intracellular accumulation 
of SI-CLP. The 1C11 mAb recognised SI-CLP in 
the cellular fraction of bronchoalveolar lavage 
specimens obtained from patients with chronic 
inﬂ  ammatory disorders of the respiratory tract and 
in PBLs from these patients as well as from healthy 
donors. Thus, 1C11 mAb can be applied for the 
examination of association of SI-CLP with human 
disorders.
SI-CLP is the only chitinase-like protein which 
is upregulated by glucocorticoids (Kzhyshkowska 
et al. 2006b). Interestingly, the highest expression 
level of SI-CLP was found by us in a patient with 
sarcoidosis undergoing corticoid therapy. We 
observed strong differences in stimulatory effect 
of dexamethasone on SI-CLP production in macro-
phages obtained from different healthy individuals. 
These facts indicate that SI-CLP is a promissing 
marker for the individual responsivity to glucocor-
ticoids and prediction of side effects of corticoid 
treatment. 
YM1 and YM2
YM1 (ECF-L) and YM2 proteins do not exist in 
human. However, domain organisation and expres-
sion proﬁ  le indicate that the function of murine 
YM1/2 can overlap with human AMCase and SI-
CLP, and we will brieﬂ  y describe the biological 
activity of YM1/2. Expression of YM1, similarly 
to AMCase and SI-CLP, is upregulated in Th2-
driven immunological reactions. YM2 is very close 
homologue of YM1, and its expression depends 
on interleukin (IL)-4 and IL-13 signal transduction 
(Webb et al. 2001). YM1/2 are mainly associated Biomarker Insights 2007: 2 142
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with two pathological situations: parasite infec-
tions and lung disorders. During the experimental 
model of murine trypanosomosis, YM1 is expressed 
on the late stage of the infection characterised by 
the conversion of classical macrophage activation 
to the alternative one (Raes et al. 2002). Expression 
of YM1 is a generalised feature of nematode infec-
tion, and YM1 together with murine AMCase are 
highly upregulated in lung of mice infected with  
Nocardia brasiliensis (Nair et al. 2005). During 
the course of allergic peritonitis, macrophages 
secrete YM1 in IL-4 and STAT6-dependent manner 
(Welch et al. 2002). YM2 is strongly upregulated 
in the lung of BALB/c mice during OVA-induced 
allergic airways inﬂ  ammation (animal model of 
asthma), where overproduction of YM2 was depen-
dent on CD4+ T-cells and on signalling of IL-4 and 
IL-13 through the IL-4Rα subunit (Webb et al. 
2001). Further, polymorphism in IL-4Rα in mice 
was shown to correlate with YM2 protein expres-
sion as well as with airways hypersensitivity and 
eosinophilia (Webb et al. 2001).
YM1, puriﬁ  ed out of supernatant of splenocytes 
of C57BL6 mice was demonstrated to possess 
chemotactic activity towards eosinophils, T-
lymphocytes and polymorphonuclear leukocytes 
in vitro, and to cause selective extravasation of 
eosinophils in vivo (Nio et al. 2004).
YM1 is crystallised in lung of motheaten mice, 
which are deﬁ  cient in SHP-1 protein-tyrosine phos-
phatase activity resulting in a broad immunological 
dysregulations including hyperreactivity of alveolar 
macrophages (Guo et al. 2000). Progressive pulmo-
nary injury in motheaten mice is characterised by 
consistent formation of intrapulmonary eosino-
philic crystals. These crystals are morphologically 
similar, but biochemically not identical to the 
Charcot-Leyden crystals in human. Crystals of 
YM1 were also found within the aged lung at sites 
of chronic inﬂ  ammation in the murine model of 
chronic granulomatosis disease (CGD) (Harbord 
et al. 2002). In human, CGD is a rare genetic disease 
caused by defects in NADPH oxidase and charac-
terised by recurrent life-threatening bacterial and 
fungal infections. In murine model of CGD, YM1 
was found in neutrophil granules, and its release 
during the acute inﬂ  ammation caused the formation 
of extracellular crystals. 
Both YM1 and Ym2 were found to be strongly 
upregulated in murine model of proliferative derma-
titis, which is characterised by accumulation of 
eosinophils (Hogenesch et al. 2006). Overexpression 
of YM1/2 in the diseased skin was due to macro-
phages, dendritic cells, and mast cells, while no detect-
able amount of YM proteins was found in eosinophils 
and neutrophils (Hogenesch et al. 2006).
In conclusion, YM1/YM2 proteins participate in 
Th2-drived allergic processes, probably via induction 
of inﬁ  ltration of inﬂ  ammatory cells, including eosin-
ophils. Whether human analogues of YM1/2proteins, 
i.e. AMCase and SI-CLP possess similar chemotactic 
activity remains to be investigated.
Oviductin/MUC9
Exclusive secretion of oviductin/MUC9 by oviductal 
epithelium and its highest expression in time of ovula-
tion gave basis for the suggestion of its regulatory role 
during fertilisation (Lok et al. 2002; Lapensee et al. 
1997). It was hypothesised that the chitinase-like 
domain of oviductin targets it to speciﬁ  c oligosac-
charide moieties in zona pellucida, where oviductin 
molecules might form protective shield around the 
oocyte (Malette et al. 1995). However, the studies 
performed in oviductin knock out mice failed to reveal 
abnormalities in fertilisation process (Araki et al. 
2003). Specific function of oviductin in human 
remains to be established.
Conclusions and perspectives
Enzymatically active chitinases chitotriosidase and 
AMCase; as well as chitinase-like proteins YKL-40, 
YKL-39 and murine YM1/2 have speciﬁ  c patterns of 
association with disorders. This pattern is deﬁ  ned by 
the cytokine-dependent expression of Glyco_18 
domain-containing proteins by various cell types. 
Serum levels of chitotriosidase and YKL-40 reﬂ  ect 
ﬁ  rst of all the activation status of macrophages, and 
in particular lipid-laden macrophages. While chitot-
riosidase is a speciﬁ  c marker for lysosomal storage 
disorders, overexpression of YKL-40 was found in 
numerous of tumors, chronic and acute inﬂ  ammations 
and during ﬁ  brosis progression. Neutrophils also 
contribute to the concentration of chitotriosidase and 
YKL-40 in the circulation. AMCase, SI-CLP and 
murine YM1/2 are expressed in Th2-environment, 
which was originally evolved for host-defence against 
parasites, while failure in control of Th2 reactions 
results in allergy and atopic asthma. Association of 
genetic markers of AMCase with bronchial asthma in 
children and animal aeroallergen asthma model indi-
cate that AMCase is involved in asthma development; 
however, it is not clear whether epithelial cells and/or 
macrophage are crucial for the secretion of AMCase Biomarker Insights 2007: 2 143
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in lung. SI-CLP is produced by macrophages, T- and 
B-cells, as well as by tumor cells. However, secretion 
of SI-CLP was detected only in case of IL-4-stimu-
lated macrophages in vitro, and further studies are 
needed to detect SI-CLP in the circulation. Novel rat 
monoclonal antibody against SI-CLP detects this 
protein with high speciﬁ  city in human BAL samples 
as well as in peripheral blood leukocytes, and will 
serve as a tool for the examination of SI-CLP asso-
ciation with human disorders. 
In conclusion, human Glyco_18 domain-
containing proteins, can be used as major and 
supplementary markers for numerous inﬂ  amma-
tory and malignant disorders. Comprehensive 
studies on large cohorts of patents are needed to 
establish the correlation of levels of Glyco_18 
domains containing proteins with currently used 
clinical markers. Further studies are needed to 
elucidate the contribution of speciﬁ  c cell types in 
secretion of chitinases and chitinase-like proteins 
into the extracellular space and into the circulation. 
Generation of knockout animal models is needed 
to investigate the physiological role of Glyco_18 
domain-proteins in the context of the whole 
organism. Understanding of physiological activity 
of chitinases and chitinase-like proteins as well as 
mechanisms of their cell-type speciﬁ  c secretion 
will allow the development of the cell-type speciﬁ  c 
therapeutic approaches. 
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